Skip to main content
PMC home page
Springer logoLink to Springer
. 2010 Nov 30;2(4):213–220. doi: 10.1007/s12402-010-0044-9

Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands

Els van den Ban 1,5,✉, Patrick C Souverein 2, Hanna Swaab 3, Herman van Engeland 5, Toine C G Egberts 2,4, Eibert R Heerdink 2,4
PMCID: PMC3000908  PMID: 21258431

Abstract

Treatment options for ADHD in the Netherlands have increased with the introduction of the extended-release formulations of methylphenidate (MPH ER, Concerta®) in 2003 and atomoxetine (ATX, Strattera®) in 2005, but data on the effect on drug usage patterns are scarce. The objective of the present study was to describe changes in the patterns of ADHD medication use and determinants thereof among children, adolescents and adults (<45 years) starting ADHD medication since the introduction of MPH ER and ATX. Data were obtained from Dutch community pharmacies as collected by the Foundation for Pharmaceutical Statistics, covering 97% of all dispenses for prescription medicines to outpatients in the Netherlands. Usage patterns (continuation, discontinuation, switching and addition) of ADHD drugs were evaluated at 3, 6 and 12 months after initiation for three separate time cohorts (patients starting ADHD medication in Jan-Dec 2002, Jan 2003–June 2004, respectively July 2004–Dec 2005). It was found that between 2002 and 2006, most ADHD drug users were initiated on methylphenidate IR. Discontinuation of any ADHD drug treatment decreased over time partly in favour of switching and addition. Discontinuation at 3 months decreased from around 33% to around 25%, at 6 months from less than 50% to almost 35%, and at 12 months from just fewer than 60% to less than 45%. Discontinuation was higher among females and in adults >18 years. After the introduction of MPH ER and ATX (time cohort III), 16.5% of the incident ADHD drug users switched their medication and almost 9% added an ADHD drug to the prior ADHD drug. In conclusion, discontinuation of incident ADHD drug use is high after 3, 6 and 12 months. During the study period, the incidence of discontinuation decreased because of the availability of extended-release methylphenidate and atomoxetine.

Keywords: Immediate-release methylphenidate, Extended-release methylphenidate, Atomoxetine, Continuation, Discontinuation, Switching, Addition, Child, Adolescent, Adult, Psychostimulant, Attention deficit hyperactivity disorder

Introduction

Attention Deficit Hyperactivity Disorder (ADHD) is a neurobiological psychiatric disorder that occurs in childhood, adolescence and adulthood. The prevalence of ADHD has been estimated at 3.0–7.5% among youth (Buitelaar 2002) and between 1.0 and 4.7% among adults (Ten Have et al. 2006; Murphy and Barkley 1996; Kessler et al. 2005; de Ridder et al. 2008). Many patients are not outgrowing their ADHD, indicating that it is a lifetime disorder requiring chronic treatment (Faraone et al. 2006). Psychopharmacological treatment is one of the most effective currently available treatment options in ADHD (Practice Parameter for the use of stimulant medications in the treatment of children, adolescents and adults 2002; Multidisciplinaire Richtlijn ADHD 2005). During the last decade, the pharmacotherapeutic options for the treatment of ADHD in the Netherlands have widened by the introduction of extended-release formulations of methylphenidate (MPH ER, Concerta®) in 2003 and the new active molecule atomoxetine (ATX, Strattera®) in 2005. Before 2003, only methylphenidate immediate release (MPH IR, Ritalin®) was approved in the Netherlands for the treatment of patients 6–18 years old with ADHD, while dexamphetamine (Dexedrin®), nortryptilin (Nortrilen®) and clonidine (Dixarit®) were used off-label for this indication.

Studies in several countries, including The Netherlands, have shown a strong increase during the last two decades in prevalence and incidence in the use of ADHD medication among preschoolers, children and adults (Robison et al. 1999, 2005; Zito et al. 2000, 2007, 2008; Miller et al. 2001; Schirm et al. 2001; Reid et al. 2002; DeBar et al. 2003; Hugtenburg et al. 2005; DosReis et al. 2005; Faber et al. 2005; Vinker et al. 2006; Castle et al. 2007; Winterstein et al. 2008; Mitchell et al. 2008; Trip et al. 2009; van den Ban et al. 2010). US data have suggested that the average duration of psychostimulant use ranges from 5 years for middle school students (Safer and Krager 1994; Angold et al. 2000) to 8 years for high school students. Dutch studies have shown a shift towards longer duration of use from 1995 to 2006 (Schirm et al. 2001; Faber et al. 2005; Trip et al. 2009). Incidences and usage patterns differ between countries and within countries because there are differences regarding use of diagnostic classification systems, practice guidelines, cultural beliefs about use of medication, reimbursement possibilities, government regulations and drug advertising (Scheffler et al. 2007; Mitchell et al. 2008; Vitiello 2008; Zito 2008). However, little is known how treatment patterns like continuation or discontinuation, switching and combining ADHD drugs have changed after the introduction of the newer ADHD drugs.

The objective of this study was to assess changes in ADHD medication usage patterns (continuation, discontinuation, switching and addition) and determinants thereof in children, adolescents and adults <45 years initiated on ADHD drugs in the Netherlands since the availability of the long-acting ADHD drugs MPH ER and ATX.

Methods

Setting and study population

Drug-dispensing data for this study were obtained from the Foundation for Pharmaceutical Statistics (Stichting Farmaceutische Kengetallen, SFK). As of 1990, SFK has been collecting dispensing data from a growing number of community pharmacies in the Netherlands. In 2001, the catchment area of SFK comprised 1,629 community pharmacies in both rural and urban areas all over the Netherlands, representing 90.7% of the total number of Dutch pharmacies. In 2006, coverage had increased to 92% of the total number of Dutch pharmacies and 97% of the Dutch population (http://www.sfk.nl). For this study, we used data from those 745 pharmacies with a complete medication history of the patients from 2001 to 2006. As the majority of patients in the Netherlands designate a single pharmacy to fill prescriptions from general practitioners or medical specialists, dispensing histories provide an almost complete account of prescription drug exposure in time (Buurma et al. 2008). Information about the prescribed medication contained patient data (anonymous ID, gender, year of birth), dispensing date, number of units dispensed and prescribed daily dose. From the SFK database, all patients born after 1960 (i.e. <45 years of age) were identified with at least one prescription dispensed between January 2002 and December 2005 for a drug approved for the treatment of ADHD (methylphenidate IR and ER, atomoxetine). From here on, these drugs will be referred to as ‘ADHD drugs’. The date of the first dispensing of an ADHD drug marked the start of follow-up. Only incident users of an ADHD drug were included in this study, where an incident user was defined as a patient having no ADHD drug dispensed during the 12 months prior. All patients were therefore required to have at least 12 months of history in the SFK database prior to this prescription date and also 12 months of follow-up after cohort-entry in order to be able to evaluate medication usage patterns. Three time cohorts were defined according to the year of ADHD drug initiation: I: January 2002–December 2002, II: January 2003–June 2004 and III: July 2004–December 2005.

ADHD drug usage patterns

For each included patient, all prescriptions for ADHD drugs were identified. The theoretical duration of use of each prescription was calculated by using information about the dispensing date, the number of units dispensed and the prescribed dosage regimen. For each subsequent dispensed prescription for an ADHD drug, the drug usage pattern was classified as continuation, discontinuation, switching or addition. Continuation was defined as continuing the initially prescribed ADHD drug. Discontinuation of ADHD treatment was defined as not having refilled a new prescription for any ADHD drug within 3 months after the theoretical end date of the previous prescription. Switching was defined as changing from one type of ADHD drug to another. Addition was defined as starting another type of ADHD drug while continuing the initially prescribed drug.

Data analysis

Demographic characteristics at baseline were compared between the three time cohorts. Age was categorized in four age strata: 0–5, 6–11, 12–17 and 18–45 years.

Patients were followed up from cohort-entry to the first change in ADHD treatment (discontinuation, switch, addition,) or censoring, whichever came first. The frequency of study outcomes for each time cohort was assessed at 3, 6 and 12 months after cohort-entry. Cox regression analysis was conducted to assess the strength of the association between determinants and discontinuation and was expressed as a hazard ratio (HR) with 95% confidence interval (CI). The association between determinants (gender, age, initial ADHD drug) and switching and addition was studied for time cohort III only, because by that time both MPH ER formulations as well as atomoxetine were available on the Dutch market.

Results

We identified 62,098 unique patients and our study population comprised 13,489 incident users of ADHD drugs (Table 1). Overall, 72.6% were male and 44.2% were aged between 6 and 11 years of age. There were no major differences in the male/female ratio and age distribution between the three time cohorts. The absolute number of patients initiating ADHD drug treatment increased over time. The vast majority of patients (93.7%) were initiated on methylphenidate IR.

Table 1.

Characteristics of incident users of ADHD drugs during 2002–2005 (N = 13,489)

Characteristics Time cohort I Jan 2002–Dec 2002 Time cohort II Jan 2003–June 2004 Time cohort III July 2004–Dec 2005 Overall 2002–2005
N = 1,849 (13.7%) N = 5,555 (41.2%) N = 6,085 (45.1%) N = 13,489 (100%)
N % N % N % N %
Sex
 Male 1,288 69.7 4,089 73.6 4,412 72.5 9,789 72.6
 Female 561 30.3 1,466 26.4 1,673 27.5 3,700 27.4
Age
 0–5 years 95 5.1 199 3.6 256 4.2 550 4.1
 6–11 years 710 38.4 2,489 44.8 2,767 45.5 5,966 44.2
 12–17 years 396 21.4 988 17.8 1,126 18.5 2,510 18.6
 18–45 years 648 35.0 1,879 33.8 1,936 31.8 4,463 33.1
Type of initial ADHD drug
MPH IR 1,849 100 5,372 96.7 5,420 89.1 12,641 93.7
MPH ER NA NA 183 3.3 549 9.0 732 5.4
ATX NA NA NA NA 116 1.9 116 0.9
Open in a new tab

NA not available at that time

Figure 1 shows the proportion of patients having one of the medication usage pattern events at 3, 6 and 12 months for the three time cohorts. The number of patients continuing the initial ADHD medication decreased over time of follow-up, and this pattern was not different between the three time cohorts. After 3 months, around two-thirds of patients were still using the original ADHD drug, but at 1 year this proportion had dropped just under 40%. In contrast, continuation of any ADHD drug treatment increased from time cohort I to time cohort III with at each measurement point (3, 6, 12 months after initiation) a relative increase in the continuation of 30–40%. The incidence of discontinuation of any ADHD drug was lower in the later time cohorts due to increased switching to and addition of the newer ADHD drugs. In time cohort III, 25% of patients had an alteration of their initial treatment: in 16.5%, the medication was switched, and in almost 9%, another ADHD drug was added to the initially prescribed drug. Overall, 90% of the switchers comprised MPH IR users, of whom almost 94% switched to MPH ER and 6% switched to ATX. Of the patients having an addition, 83% were MPH IR users and most of them were added MPH ER (data not shown).

Fig. 1.

Fig. 1

Open in a new tab

Percentage of incident users having encountered one of the outcome events at 3, 6 and 12 months for the three time cohorts I, II, III. Time cohort I January 2002–December 2002, time cohort II January 2003–June 2004, time cohort III July 2004–December 2005

Table 2 shows that the proportion of patients of discontinuing of ADHD drug users was higher among females (72.0%) than among men (60.3%), yielding an adjusted HR of 1.09 (95% CI 1.04–1.15) and among adults >18 years (adjusted HR 1.13, 95% CI: 1.06–1.19 vs. 12–17 year olds) in this particular study period. The influence of the determinants did not differ between the three time cohorts.

Table 2.

Risk of ADHD treatment discontinuation during total follow-up (N = 13,489)

Characteristics Number % Discontinued Crude HR (95% CI) Adjusted HR (95% CI)a
Time cohort
 Jan 2002–Dec 2002 1,458 78.9 1.00 (reference) 1.00 (reference)
 Jan 2003–June 2004 3,864 69.6 0.86 (0.81–0.91) 0.98 (0.92–1.04)
 July 2004–Dec 2005 3,248 53.4 0.70 (0.66–0.75) 0.86 (0.81–0.92)
Sex
 Male 5,907 60.3 1.00 (reference) 1.00 (reference)
 Female 2,663 72.0 1.39 (1.32–1.45) 1.09 (1.04–1.15)
Age category
 0–5 years 294 53.5 0.64 (0.57–0.72) 0.67 (0.59–0.75)
 6–11 years 2,910 48.8 0.52 (0.49–0.56) 0.53 (0.50–0.56)
 12–17 years 1,810 72.1 1.00 (reference) 1.00 (reference)
 18–45 years 3,556 79.7 1.37 (1.29–1.45) 1.13 (1.06–1.19)
Open in a new tab

aAdjusted for other characteristics in Table 2

Discussion

First, this study showed that the discontinuation rate of treatment with ADHD drugs is high in all three time cohorts after 3, 6 and 12 months, especially among women and adults. Second, over time the discontinuation rate of any ADHD drug use decreased because of increased switching and addition following the availability of the newer ADHD drugs MPH ER and ATX.

The discontinuation frequency in our study is within the same range as found in other studies. Between 36 and 51% of the children discontinued their ADHD medication within 1 year after start (Bussing et al. 2005; Winterstein et al. 2008). Only half of the children received their ADHD medication for less than 3 years (Prosser and Reid 2009). On the other hand, 77% of the parents of children (6–18 years) diagnosed with ADHD reported in an online questionnaire that the length of treatment was more than 1 year (Coghill et al. 2008). In the Netherlands, a retrospective study of patients aged 6–21 years in an outpatient clinic for child and adolescent psychiatry showed that less than 10% discontinued their medication and half of the patients switched at least once between 2005 and 2006 (Pauw et al. 2008). Studies in adults also report high discontinuation rates. Only 24% of the patients initiated on methylphenidate were still on treatment after 7 months (Capone and McDonnel 2006). About 20% of the adult ADHD patients in Norway still used their medication after 2 years between 1997 and 2003 (Aanonsen et al. 2004).

In our study, risk of discontinuation was higher among females. This finding is in contrast with results from Faber et al. (2005), who found no difference in duration of stimulant use between boys and girls, but supports data from Trip et al. (2009), who found that boys tended to use their ADHD medication longer than girls. A recent Australian study (Prosser and Reid 2009) found a decline in the duration of treatment with ADHD drugs from 2.5 years in 1990–2000 to 2 years in 2000–2006 with no difference between boys and girls aged less than 18 years. Their finding is consistent with studies by Reid et al. (2002) and Barbaresi et al. (2006). Differences in outcome of discontinuation rates can be caused by study design, inclusion of different ages, the prescriber, the treatment setting, the motivation of patient and parents, duration of follow-up and as in our study the introduction of newer ADHD drugs.

In time cohort III, after the introduction of MPH ER and ATX, 16.5% of the incident ADHD drug users switched their medication, mainly MPH IR to ER and almost 9%, of whom 17% was adult, added an ADHD drug to the prior ADHD drug, mainly MPH ER to IR. This is consistent with the study of Pauw et al (2008) in which eighty per cent switched from MPH IR to ER. Our hypothesis is that switching from MPH IR to ER is associated with a greater continuity of treatment than MPH IR. This is confirmed in studies in youth (Marcus et al. 2005; Lage and Hwang 2004) and adults (Olfson et al. 2007). Switching to the non-stimulant drug ATX is probably because of side effects or too little effect of MPH IR.

There are several studies on pharmacological monotherapy versus combined therapy for ADHD in youth. Combined use of methylphenidate IR, ER or atomoxetine has not been the main subject of a study, although some data are available. Only 7% of the Australian children, 3–17 years old, received a combination of MPH IR and ER in 2004 (Preen et al. 2007). Less than 2% of the children between 2006 and 2008 used more than one psychostimulant (Thompson et al. 2009). In adults, combined use of ADHD drugs was determined in 19.7% of initial atomoxetine users, in 21.0% of initial extended-release stimulant users and in 23.1% of the initial immediate-release stimulant users between July 2003 and June 2004 (Pohl et al. 2009). Hyperactivity predicted the combined use of ADHD medication in adults initiated on atomoxetine.

As if ADHD can be seen as a lifetime disorder, it should need chronic treatment. Medication is one of the most powerful treatment options in ADHD (Faraone et al. 2006). The high discontinuation rate in our study may reflect suboptimal treatment for ADHD. Untreated ADHD is a risk factor for traffic accidents, emergency room visits, school, work and marital problems, substance abuse and psychopathology (Fischer et al. 1990; Barkley et al. 1993, 1996; Mannuzza et al. 1993; DiScala et al.1998; Leibson et al. 2001; Wilens 2004; Sobanski et al. 2008a, b). Probably with the introduction of long-acting ADHD medication continuation of treatment can be optimized. In children (6–17 year) and adults, initial use of MPH ER was associated with a longer duration of treatment compared to the initial use of MPH IR (Lage and Hwang 2004; Marcus et al. 2005; Olfson et al. 2007). There are indications that patients with more severe ADHD symptoms switch more rapidly to long-acting drugs (Gau et al. 2008). There are several reasons for discontinuation. Psychostimulants can have a rapid effect on ADHD symptoms, and ADHD drug users can think that they are cured by the medication and stop. They can suffer from side effects or they disbelieve in the effects of medication. The type of prescriber or setting can influence their compliance. Probably, the ADHD drug user did not suffer from ADHD or other treatment opportunities were available and effective in reducing the ADHD symptoms.

Strengths of this study were that it was population based and involved a large sample of persons using ADHD medication. There are several limitations. We had no information on the indication for which ADHD drugs were prescribed. Although methylphenidate is the first-choice pharmacotherapeutical intervention in the treatment of ADHD for children, adolescents (Practice Parameter for the use of stimulant medications in the treatment of children, adolescents and adults 2002; Multidisciplinaire Richtlijn ADHD 2005) and adults (Kooij 2003; Spencer et al. 2005), it can also be prescribed to adults for somatic problems (Donker et al. 2005; Gagnon et al. 2005). Furthermore, persistence of ADHD treatment might have been affected by the prescriber, treatment setting or high costs of long-acting medication, which are not always covered by health insurance companies. Little is known about the influence of studies or guidelines on ADHD drug treatment published in professional journals (inter)national conventions or marketing strategies of pharmaceutical companies on the prescribing behaviour of health care professionals or the perception on ADHD symptoms and medication of patients, parents or teachers (Layton et al. 2008). These factors may contribute to a more or less tolerant attitude towards ADHD drugs. The Dutch clinical guideline was presented just before the introduction of atomoxetine in the Netherlands and could have influenced prescription behaviour.

In conclusion, discontinuation of ADHD drugs use is high within 1 year after initiation. It decreased over calendar time since the availability of long-acting ADHD drugs, which make it possible to switch or use more than one ADHD drug at the same time. Combined ADHD drug therapy is not very common in the Netherlands. More research on continuation, discontinuation, switching and addition must be performed after 2006 to investigate whether prescription of long-acting drugs further decreases the rate of discontinuation. Backgrounds of switching to MPH ER or ATX and effects of discontinuation of ADHD drugs on school performance, comorbidity, marital and family stress should be subject of future research.

Acknowledgments

Conflict of interest

E van den Ban: Janssen-Cilag BV: lecture, reimbursed travel to convention; Lilly Nederland BV: scientific research (no personal grant), lecture, advisory board, reimbursed travel to convention; UCB Pharma BV: advisory board, reimbursed travel to convention: Eurocept BV: lecture (no personal grant), reimbursed travel to convention. The division of Pharmacoepidemiology & Clinical Pharmacology employing authors PS, RH and TE has received unrestricted funding for pharmacoepidemiological research from GlaxoSmithKline, Novo Nordisk, the private-public funded Top Institute Pharma (http://www.tipharma.nl, includes co-funding from universities, government, and industry), the Dutch Medicines Evaluation Board, and the Dutch Ministry of Health. No support or funding for this manuscript.

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Abbreviations

ADHD

Attention deficit hyperactivity disorder

MPH IR

Methylphenidate immediate release

MPH ER

Methylphenidate extended release

ATX

Atomoxetine

References

  1. Aanonsen N, Lensing M, Prietz R. Utproevende behandling med snetralstimulerende legemidler tol vokse men hyperkinetisk forstyrrelse/ADHD. Oslo: Ullevaal University Hospital; 2004. [Google Scholar]
  2. American Academy of Child and Adolescent Psychiatry Practice parameter for the use of stimulant medications in the treatment of children, adolescents and adults. J Am Acad Child Adolesc Psychiatry. 2002;41(suppl 2):26S–49S. doi: 10.1097/00004583-200202001-00003. [DOI] [PubMed] [Google Scholar]
  3. Angold A, Erkanli A, Egger HL, Costello EJ (2000). Stimulant treatment for children: a community perspective. J Am Acad Child Adolesc Psychiatry 39:975–984 (discussion 984–994) [DOI] [PubMed]
  4. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr. 2006;27:1–10. doi: 10.1097/00004703-200602000-00001. [DOI] [PubMed] [Google Scholar]
  5. Barkley R, Fischer M, Edelbrock C, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria—III. Mother-child interactions, family conflicts and maternal psychopathology. J Child Psychol Psychiatry. 1991;32(2):233–255. doi: 10.1111/j.1469-7610.1991.tb00304.x. [DOI] [PubMed] [Google Scholar]
  6. Barkley R, Guevremont D, Anastopoulos A, DuPaul G, Shelton T. Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3- to 5-year follow-up survey. Pediatrics. 1993;92(2):212–218. [PubMed] [Google Scholar]
  7. Barkley RA, Murphy KR, Kwasnik D. Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics. 1996;98(6):1089–1095. [PubMed] [Google Scholar]
  8. Buitelaar J (2002) Epidemiological aspects: what have we learned over the last decade? In: Sandberg S (ed) Hyperactivity and attention disorders of childhood. Cambridge University Press, Cambridge, pp 30–64
  9. Bussing R, Zima B, Mason D, Hou W, Wilson Garvan C, Forness S. Use and persistence of pharmacotherapy for elementary school students with attention-deficit/hyperactivity disorder. J Child Adoles Psychopharmacol. 2005;15:78–87. doi: 10.1089/cap.2005.15.78. [DOI] [PubMed] [Google Scholar]
  10. Buurma H, Bouvy M, De Smet P, Floor-Schreudering A, Leufkens H, Egberts A. Prevalence and determinants of pharmacy shopping behaviour. J Clin Pharm Ther. 2008;33:17–23. doi: 10.1111/j.1365-2710.2008.00878.x. [DOI] [PubMed] [Google Scholar]
  11. Capone N, McDonnel T (2006) Medication persistence among agents used to treat attention-deficit/hyperactivity disorder, diabetes, and elevated serum cholesterol. In: American Psychiatric Association 2006 annual meeting. American Psychiatric Association, Toronto
  12. Castle L, Aubert R, Verbrugge R, Khalid M, Epstein R. Trends in medication treatment for ADHD. J Atten Disord. 2007;10:335–342. doi: 10.1177/1087054707299597. [DOI] [PubMed] [Google Scholar]
  13. Coghill D, Soutullo C, d’Aubuisson C, Preuss U, Lindback T, Silverberg M, Buitelaar J. Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey. Child Adoles Psychiatry Mental Health. 2008;2:31–46. doi: 10.1186/1753-2000-2-31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. de Ridder T, Bruffaerts R, Danckaerts M, Bonnewyn A, Demyttenaere K. ADHD in de Belgische bevolking; een epidemiologische exploratieve studie. Tijdschrift voor Psychiatrie. 2008;8:499–508. [PubMed] [Google Scholar]
  15. DeBar LL, Lynch F, Powell J, Gale J. Use of psychotropic agents in preschool children: associated symptoms, diagnoses, and health care services in a health maintenance organization. Arch Pediatrics Adoles Med. 2003;157:150–157. doi: 10.1001/archpedi.157.2.150. [DOI] [PubMed] [Google Scholar]
  16. DiScala C, Lescohier I, Barthel M, Li G. Injuries to children with attention deficit hyperactivity disorder. Pediatrics. 1998;102(6):1415–1421. doi: 10.1542/peds.102.6.1415. [DOI] [PubMed] [Google Scholar]
  17. Donker G, Groenhof F, van der Veen W. Toenemend aantal voorschriften voor methylfenidaat in huisartsenpraktijken in Noordoost-Nederland, 1998–2003. Nederlands Tijdschrift voor Geneeskunde. 2005;149:1742–1747. [PubMed] [Google Scholar]
  18. DosReis S, Zito JM, Safer DJ, Gardner JF, Puccia KB, Owens PL. Multiple psychotropic medication use for youths: a two-state comparison. J Child Adoles Psychopharmacol. 2005;15:68–77. doi: 10.1089/cap.2005.15.68. [DOI] [PubMed] [Google Scholar]
  19. Faber A, van den Jong de-Berg L, van den Berg van den P, Tobi H. Psychotropic co-medication among stimulant-treated children in the Netherlands. J Child Adoles Psychopharmacol. 2005;15:38–43. doi: 10.1089/cap.2005.15.38. [DOI] [PubMed] [Google Scholar]
  20. Faraone S, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow up studies. Psychol Med. 2006;36:159–165. doi: 10.1017/S003329170500471X. [DOI] [PubMed] [Google Scholar]
  21. Fischer M, Barkley R, Edelbrock C, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: II. Academic, attentional, and neuropsychological status. J Consult Clin Psychol. 1990;58(5):580–588. doi: 10.1037/0022-006X.58.5.580. [DOI] [PubMed] [Google Scholar]
  22. Gagnon B, Low G, Schreyer G. Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci. 2005;30:100–107. [PMC free article] [PubMed] [Google Scholar]
  23. Gau SS, Chen SJ, Chou WJ, Cheng H, Tang CS, Chang HL, Tzang RF, Wu YY, Huang YF, Chou MC, Liang HY, Hsu YC, Lu HH, Huang YS. National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Clin Psychiatry. 2008;69:131–140. doi: 10.4088/JCP.v69n0118. [DOI] [PubMed] [Google Scholar]
  24. http://www.keele.ac.uk/schools/pharm/MTRAC/ProductInfo/verdicts/A/ATOMOXETINE.PDF
  25. Hugtenburg J, Heerdink E, Egberts A. Increased psychotropic drug consumption by children in the Netherlands during 1995–2001 is caused by increased use of methylphenidate by boys. Eur J Clin Pharmacol. 2005;60:377–379. doi: 10.1007/s00228-004-0765-9. [DOI] [PubMed] [Google Scholar]
  26. Kessler R, Adler L, Ames M, Barkley R, Birnbaum H, Greenberg P, Johnston J, Spencer T, Ustun T. The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med. 2005;47:565–572. doi: 10.1097/01.jom.0000166863.33541.39. [DOI] [PubMed] [Google Scholar]
  27. Kooij J. ADHD bij volwassenen. Inleiding in diagnostiek en behandeling. ADHD in adults. Introduction and treatment. Lisse: Swets & Zeitlinger Publishers; 2003. [Google Scholar]
  28. Lage M, Hwang P. Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. J Child Adoles Psychopharmacol. 2004;14:575–581. doi: 10.1089/cap.2004.14.575. [DOI] [PubMed] [Google Scholar]
  29. Layton D, Souverein P, Heerdink E, Shakir S, Egberts A (2008) Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users. A cohort study using pharmacy dispensing data in the Netherlands. Drug Safety 31:143–158 [DOI] [PubMed]
  30. Leibson CL, Katusic SK, Barbaresi WJ, Ransom J, O’Brien PC. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. J Am Med Assoc. 2001;285(1):60–66. doi: 10.1001/jama.285.1.60. [DOI] [PubMed] [Google Scholar]
  31. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry. 1993;50:565–576. doi: 10.1001/archpsyc.1993.01820190067007. [DOI] [PubMed] [Google Scholar]
  32. Marcus S, Wan G, Kemner J, Olfson M. Continuity of methylphenidate treatment for attention deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2005;159:572–578. doi: 10.1001/archpedi.159.6.572. [DOI] [PubMed] [Google Scholar]
  33. Miller A, Lalonde C, McGrail K, Armstrong R. Prescription of methylphenidate to children and youth, 1990–1996. Can Med Assoc. 2001;165:1489–1494. [PMC free article] [PubMed] [Google Scholar]
  34. Mitchell B, Carleton B, Smith A, Prosser R, Brownell M, Kozyrskyj A. Trends in psychostimulant and antidepressant use by children in 2 canadian provinces. La Revue de Psychiatry. 2008;53:152–159. doi: 10.1177/070674370805300305. [DOI] [PubMed] [Google Scholar]
  35. Multidisciplinaire Richtlijn ADHD bij kinderen en jeugdigen . Richtlijn voor diagnostiek en behandeling van ADHD bij kinderen en jeugdigen (Multidisciplinairy Guideline for diagnosis and treatment of ADHD of children and adolescents) Utrecht: Trimbos Instituut; 2005. [Google Scholar]
  36. Murphy K, Barkley R. Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: Implications for clinical diagnosis. J Atten Disord. 1996;3:147–161. doi: 10.1177/108705479600100303. [DOI] [Google Scholar]
  37. Olfson M, Marcus M, Zhang H, Wan G : Continuity in methylphenidate treatment of adults with attention-deficit/hyperactivity disorder. J Manag Care Pharmacy. 2007;13:570–577. doi: 10.18553/jmcp.2007.13.7.570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Pauw R, Dieleman H, de Vogel de E, Eussen M. Retrospectief, observationeel onderzoek naar switchen en stoppen van ADHD-medicatie. Pharmaceutisch Weekblad, Wetenschappelijk Platform. 2008;2:183–187. [Google Scholar]
  39. Pohl GM, Van Brunt DL, Ye W, Stoops WW, Johnston JA. A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD) BMC Health Serv Res. 2009;8:95–103. doi: 10.1186/1472-6963-9-95. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Preen DB, Calver J, Sanfilippo FM, Bulsara M, Holman CD. Patterns of psychostimulant prescribing to children with ADHD in Western Australia: variations in age, gender, medication type and dose prescribed. Aust N Z J Public Health. 2007;31:120–126. doi: 10.1111/j.1753-6405.2007.00028.x. [DOI] [PubMed] [Google Scholar]
  41. Prosser B, Reid R. Changes in use of psychostimulant medication for ADHD in South Australia (1990–2006) Aust N Z J Psychiatry. 2009;43:340–347. doi: 10.1080/00048670902721129. [DOI] [PubMed] [Google Scholar]
  42. Reid R, Hakendorf P, Prosser B. Use of stimulant medication for ADHD in South Australia. J Am Acad Child Adoles Psychiatry. 2002;41:906–913. doi: 10.1097/00004583-200208000-00008. [DOI] [PubMed] [Google Scholar]
  43. Robison L, Sclar D, Traer T, Galins R. National trends in prevalence of attention-deficit/hyperactivity disorder and the prescription of methylphenidate among school-age children: 1990–1995. Clin Pediatr. 1999;38:209–217. doi: 10.1177/000992289903800402. [DOI] [PubMed] [Google Scholar]
  44. Robison L, Sclar D, Skaer T. Trends in ADHD and stimulant use among adults: 1995–2002. Psychiatr Serv. 2005;56:1497. doi: 10.1176/appi.ps.56.12.1497. [DOI] [PubMed] [Google Scholar]
  45. Safer DJ, Krager JM. The increased rate of stimulant treatment for hyperactive/inattentive students in secondary schools. Pediatrics. 1994;94:462–464. [PubMed] [Google Scholar]
  46. Scheffler R, Hinshaw S, Modrek S, Levine P. The global market for ADHD medications. Health Aff. 2007;26:450–457. doi: 10.1377/hlthaff.26.2.450. [DOI] [PubMed] [Google Scholar]
  47. Schirm E, Tobi H, Zito J, van den Jong de-Berg L. Psychotropic medication in children: a study from the Netherlands. Pediatrics. 2001;108:E25–E29. doi: 10.1542/peds.108.2.e25. [DOI] [PubMed] [Google Scholar]
  48. Sobanski E, Sabljic D, Alm B, Skopp G, Kettler N, Mattern R, Strohbeck-Kühner P. Driving-related risks and impact of methylphenidate treatment on driving in adults with attention-deficit/hyperactivity disorder (ADHD) J Neural Trans. 2008;115:347–356. doi: 10.1007/s00702-007-0834-1. [DOI] [PubMed] [Google Scholar]
  49. Sobanski E, Brüggemann D, Alm B, Kern S, Philipsen A, Schmalzried H, Hesslinger B, Waschkowski H, Rietschel M. Subtype differences in adults with attention-deficit/hyperactivity disorder (ADHD) with regard to ADHD-symptoms, psychiatric comorbidity and psychosocial adjustment. Eur Psychiatry. 2008;23:142–149. doi: 10.1016/j.eurpsy.2007.09.007. [DOI] [PubMed] [Google Scholar]
  50. Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, Mick E, Aleardi M, Herzig K, Faraone S. A large, double-blind, randomized clinical trial of methylphenidate treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:456–463. doi: 10.1016/j.biopsych.2004.11.043. [DOI] [PubMed] [Google Scholar]
  51. Ten Have M, de Graaf R, Dorsselaer S, Verdurmen J, Land van’t H, Vollenbergh W, Ormel J. Prevalentie van impulsstoornissen. Resultaten van the European Study of Epidemiology of Mental Disorders (ESEMeD) Utrecht: Trimbos Instituut; 2006. [Google Scholar]
  52. Thompson J, Varley C, McClellan J, Hilt R, Lee T, Kwan A, Lee T, Trupin E. Second opinions improve ADHD prescribing in a medicaid-insured community population. J Am Acad Child Adoles Psychiatry. 2009;48:740–748. doi: 10.1097/CHI.0b013e3181a2b2ed. [DOI] [PubMed] [Google Scholar]
  53. Trip A, Visser S, Kalverdijk L, de Jong-van den Berg L. Large increase of the use of psycho-stimulants among youth in the Netherlands between 1996 and 2006. Br J Clin Pharmacol. 2009;67:466–468. doi: 10.1111/j.1365-2125.2009.03373.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. van den Ban E, Souverein P, Swaab H, van Engeland H, Heerdink R, Egberts T. Trends in incidence and characteristics of children, adolescents and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001–2006. J Child Adoles Psychopharmacol. 2010;20:55–61. doi: 10.1089/cap.2008.0153. [DOI] [PubMed] [Google Scholar]
  55. Vinker S, Vinker R, Elhayany A. Prevalence of methylphenidate use among Israeli children: 1998–2004. Clin Drug Invest. 2006;26:161–167. doi: 10.2165/00044011-200626030-00006. [DOI] [PubMed] [Google Scholar]
  56. Vitiello B. An international perspective on pediatric psychopharmacology. Int Rev Psychiatry. 2008;20:121–126. doi: 10.1080/09540260801887710. [DOI] [PubMed] [Google Scholar]
  57. Wilens TE. Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. Psychiatr Clin North Am. 2004;27:283–301. doi: 10.1016/S0193-953X(03)00113-8. [DOI] [PubMed] [Google Scholar]
  58. Winterstein A, Gerhard T, Shuster J, Zito J, Johnson M. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in medicaid database. Ann Pharmacother. 2008;42:24–31. doi: 10.1345/aph.1K143. [DOI] [PubMed] [Google Scholar]
  59. Zito J, Safer D, dosReis S, Gardner J, Boles M, Lynch F. Trends in prescribing of psychotropic medications to preschoolers. J Am Med Assoc. 2000;283:1025–1030. doi: 10.1001/jama.283.8.1025. [DOI] [PubMed] [Google Scholar]
  60. Zito J, Safer D, Satish Valluri M, Gardner J, Korelitz J, Mattison D. Psychotherapeutic medication prevalence in medicaid-insured preschoolers. J Child Adoles Psychopharmacol. 2007;17:195–203. doi: 10.1089/cap.2007.0006. [DOI] [PubMed] [Google Scholar]
  61. Zito JM, Safer DJ, Berg LT, Janhsen K, Fegert JM, Gardner JF, Glaeske G, Valluri SC. A three-country comparison of psychotropic medication prevalence in youth. Child Adoles Psychiatry Mental Health. 2008;25:26–34. doi: 10.1186/1753-2000-2-26. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Attention Deficit and Hyperactivity Disorders are provided here courtesy of Springer

RESOURCES